Compare COO & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COO | DVA |
|---|---|---|
| Founded | 1980 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 14.9B |
| IPO Year | 1994 | 2003 |
| Metric | COO | DVA |
|---|---|---|
| Price | $53.91 | $181.55 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 4 |
| Target Price | $90.18 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 1.8M | 552.1K |
| Earning Date | 05-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 2.49 | ★ 6.86 |
| Revenue | $2,532,800,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | $6.66 | $3.85 |
| Revenue Next Year | $5.18 | $3.07 |
| P/E Ratio | $235.11 | ★ $26.68 |
| Revenue Growth | ★ 18.41 | 6.46 |
| 52 Week Low | $58.89 | $101.00 |
| 52 Week High | $89.83 | $247.49 |
| Indicator | COO | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 14.42 | 42.41 |
| Support Level | N/A | $176.59 |
| Resistance Level | $73.39 | $202.63 |
| Average True Range (ATR) | 1.87 | 4.77 |
| MACD | -1.66 | 2.21 |
| Stochastic Oscillator | 16.24 | 71.79 |
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.